Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Open-Label Pilot Study of Granulocyte Colony Stimulating Factor (G-CSF) to Preserve Brain Structure and Function Following Standard Chemoradiation in Patients With Newly Diagnosed MGMT-Methylated Glioblastoma

NCT06649851 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT06649851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Open-Label Pilot Study of Granulocyte Colony Stimulating Factor (G-CSF) to Preserve Brain Structure and Function Following Standard Chemoradiation in Patients With Newly Diagnosed MGMT-Methylated Glioblastoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 2, 2025
Completion date
January 31, 2030
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm), mgmt-methylated glioblastoma, newly diagnosed glioblastoma multiforme